Barclays lowered the firm’s price target on Lumexa Imaging (LMRI) to $15 from $23 and keeps an Overweight rating on the shares after meeting with management. The company reiterated its 2026 outlook, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LMRI:
- Lumexa Imaging Reaffirms Full-Year 2026 Financial Guidance
- Lumexa Imaging Earnings Call Highlights Growth Momentum
- Maintaining Buy on LMRI: Market Overdiscounts Consolidated Centers, Creating Upside to $17 Target
- Lumexa Imaging price target lowered to $17 from $23 at Raymond James
- Lumexa Imaging Holdings Inc trading resumes